logo
What causes Parkinson's disease? Scientists uncover an unexpected new clue.

What causes Parkinson's disease? Scientists uncover an unexpected new clue.

Yahoo23-07-2025
More than 10 million people worldwide are living with Parkinson's disease, a progressive neurodegenerative disorder that leads to symptoms such as tremors, slow movement, limb stiffness, and balance issues. Scientists still don't know what causes the disease, but it's thought to develop due to a complex mixture of genetic and environmental factors, and treatment is still quite limited.
But new research is putting scientists one step closer to some possible answers.
In a recent study published in JCI Insight, researchers found a common virus, called human pegivirus (HPgV), in the brains of patients who had Parkinson's disease when they died. Although HPgV infections don't usually cause symptoms, researchers believe the virus may be playing a role in the development of Parkinson's.
'The hypothesis is that a long-term, low-burning infection might lead to these sorts of diseases,' such as Parkinson's disease and other neurodegenerative disorders, says Barbara Hanson, a researcher at Northwestern University Feinberg School of Medicine, and one of the authors of the paper.
Here's what we know so far.
Over 500 viruses screened
In this study, researchers screened for over 500 viruses in the autopsied brains of 10 patients who had Parkinson's disease and compared them to the autopsied brains of 14 control patients, who were matched for age and gender. In five of the patients with Parkinson's, they found the presence of HPgV, while none of the control patients had the virus.
In order to bolster their findings, researchers conducted follow-up experiments that looked at the blood samples of patients who were in different stages of Parkinson's disease. What they found was that patients who had Parkinson's and were positive for HPgV had similar immune system responses, including a lower level of an inflammatory protein called IL-4, which can either promote or suppress inflammation depending on the situation.
They also found that patients who had a specific Parkinson's-related gene mutation had a different immune system response to HPgV, compared to patients with Parkinson's who didn't have the mutation. 'It was a very thorough study,' says Margaret Ferris, a neurologist and researcher at Stanford University who was not part of the study. She adds that this offers a possible mechanism for the interaction between genetics and environment.
Why Parkinson's disease is so hard to study
Although the presence of HPgV in the brains of people with Parkinson's disease is suggestive of a link, the full answer of what causes the neurodegenerative disease is more complex.
Parkinson's disease has always been hard to study, due to the fact that it develops slowly, over many years, and is difficult to diagnose in the earlier stages. 'One of the hard things about investigating neurodegenerative disorders is that it is very hard to identify people who will get neurodegenerative disorders, but don't yet have them, and to study and watch them,' Ferris says.
Further complicating this matter is the fact that there doesn't seem to be one single trigger for Parkinson's disease. 'It is difficult to determine the causes of Parkinson's, because they are likely multifactorial,' says William Ondo, a neurologist at Houston Methodist Hospital, who specializes in treating patients with movement disorders such as Parkinson's disease. Ondo was not part of the study.
Currently, Parkinson's disease is believed to develop from a complex mixture of genetic and environmental factors, with individual triggers varying from one person to another. This makes studying the potential causes of the disease quite challenging, and means that there still aren't definitive answers to what can trigger the condition. It's likely that some people may develop Parkinson's disease as a result of multiple triggers.
'Everyone is on their own path,' to developing Parkinson's disease, says Erin Furr-Stimming, a neurologist at McGovern Medical School at UTHealth Houston, who was not part of the study.
Link between viral infections and neurodegeneration
In recent years, there has been a growing body of evidence to suggest a link between viral infections and the development of neurological diseases, such as multiple sclerosis, Alzheimer's, and Parkinson's. This includes the recent discovery that Epstein-Barr virus is a major trigger for multiple sclerosis, as well as a number of associations between viral infections and neurodegenerative conditions. Parkinson-like symptoms have also been triggered by a number of viral infections, such as West Nile virus, St. Louis Encephalitis virus, and Japanese Encephalitis B Virus.
As Hanson notes, inflammation in the brain has been linked to the development of neurodegenerative disorders, with viral infections being a potential trigger for this inflammation.
'Any amount of inflammation in the brain can trigger a number of cascades that lead to the loss of normal homeostatic brain function,' Hanson says. 'It's possible that viral infections are one of those triggers that lead to inflammation in the brain.' Other potential reasons that viral infections may lead to neurodegeneration include direct damage to neurons from the virus, or the accumulation of misfolded proteins.
However, while this recent study offers evidence of a suggested link between HPgV and the development of Parkinson's disease, there's still more research needed before a clear link between the two can be established.
'This study doesn't show a cause-and-effect relationship—it just suggests there may be a relationship between pegivirus and Parkinson's,' says Joseph Jankovic, a neurologist and director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine. In order to understand the connection further, Jankovic says, 'this study needs to be replicated in a different cohort of patients.'
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

Yahoo

time23 minutes ago

  • Yahoo

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

BRISBANE, Calif., August 06, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx," said John Hanna, CEO of CareDx. "His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase." In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. "On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO," said John Hanna. "Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best." About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts CareDx Media Contacts Natasha Moshirian Wagnernwagner@ Investor RelationsCaroline Cornerinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

Yahoo

time23 minutes ago

  • Yahoo

FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths

WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Baltimore organizations try to keep the momentum going with overdose prevention
Baltimore organizations try to keep the momentum going with overdose prevention

CBS News

time25 minutes ago

  • CBS News

Baltimore organizations try to keep the momentum going with overdose prevention

Some Baltimore organizations are working around the clock to combat drug abuse while trying to prevent residents from overdosing. The Pride Center of Maryland's Harm Reduction Team was in action on Wednesday in the city's Old Gaucher neighborhood, handing out resources, including Narcan. Those getting this help say this work is sorely needed, adding it's a life-or-death situation. Every day, members of the Pride Center of Maryland's Harm Reduction Team are outside the nonprofit's resource center on Maryland Avenue. They're sitting at tables, which are filled with food, hygiene products, clothes -- as well as Narcan, fentanyl strips, and other health resources. It's free for anyone who walks by. Jerome Scott, the Pride Center's program manager of wellness, said the purpose is about visibility and to let people know they are here to help. "[Let people know] we see you, we care, and we have things for you," Scott said. "We just like to let our faces be known." But, they aren't just stationary. Scott packed a few drawstring bags with what was on the tables and walked several blocks around the neighborhood, handing them out to anyone he saw. A volunteer also handed out lunches alongside him. Scott said there are times he would leave Narcan and other resources in certain locations, even if no one is there, so it can be readily accessible if someone were to use it nearby. Scott stressed that it's important this work doesn't lose momentum. "These are our brothers, these are our sisters, our aunts, our uncles out here. So, we wanna be there for them," Scott said. Scott said the mass overdoses in the Penn North neighborhood in July show why this work can't slow down. Penn North is another neighborhood where Scott does outreach and brings resources to. Jessica Collins, who received some of the Pride Center's free resources, said she's also been in an addiction treatment center since May. She said these resources need to be more accessible to encourage addicts to get help. "It's just each individual taking that step to go forward to wanting that that person making that decision to want to get help," Collins said. When asked how much Narcan his team has on hand, Scott said they try to have at least 500. However, the team goes through its inventory often, especially in the summer months.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store